The trajectory of companies tied to Sildenafil's history presents a intricate investment scenario . While the initial success generated substantial profits , generic alternatives have significantly diminished revenue. Investing in related pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving medical changes,